Ebvallo
Ebvallo is a medicine authorised by Swissmedic under authorisation number 69052. The authorisation holder is Pierre Fabre Pharma SA. The medicinal product code is Transplant: cell therapy product and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 03 May 2024 and the authorisation is limited until 02 May 2029. ATC code L01XL09 places the medicine in the group Antineoplastic agents.
| Authorisation number | 69052 |
|---|---|
| Name | Ebvallo |
| Full name | Ebvallo, Injektionsdispersion |
| Authorisation holder | Pierre Fabre Pharma SA |
| Medicinal product code | Transplant: cell therapy product |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01XL09 |
| First authorisation | 03 May 2024 |
| Authorisation validity | 02 May 2029 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Ebvallo, Injektionsdispersion | A | 03 May 2024 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 bis 6 | Durchstechflasche(n) | L01XL09 | 07.16.4. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Ebvallo authorised in Switzerland?
Yes. Ebvallo is authorised by Swissmedic under authorisation number 69052, data as of 01 September 2026. The authorisation is limited until 02 May 2029.
Which dispensing category does Ebvallo have?
Ebvallo is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Ebvallo?
The authorisation holder is Pierre Fabre Pharma SA. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.